Litcius/Paper detail

A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)

Federico Martinón‐Torres, Jacek Wysocki, Leszek Szenborn, Alfonso Carmona-Martinez, Airi Põder, Ron Dagan, Peter Richmond, Christopher L. Gilbert, Marie-Chantale Trudel, Sheryl Flores, Robert Lupinacci, Richard McFetridge, Richard T. Wiedmann, Qiuxu Chen, Han Gerrits, Natalie Banniettis, Luwy Musey, Kara Bickham, Janusz Kaminski

2023Vaccine28 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePneumococcal conjugate vaccineConfidence intervalToddlerSerotypeAdverse effectImmunogenicityVaccinationTolerabilityRandomized controlled trialNeutralizing antibodySeroconversionPediatricsStreptococcus pneumoniaeInternal medicineAntibodyImmunologyMicrobiologyBiologyAntibioticsPsychologyDevelopmental psychologyPneumonia and Respiratory InfectionsRespiratory viral infections researchAdvanced Causal Inference Techniques
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1) | Litcius